Executive readout · one minute
Webcast research workspace
Read the call alongside every captured source. Transcript, audio stay in one workspace.
Conference · 2026-05-13
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Executive readout · one minute
Read the call alongside every captured source. Transcript, audio stay in one workspace.
Research coverage
2 live sources
Switch sources without leaving this page or losing your listening position.
Open the source you need; every reader stays inside this workspace.
Thanks for joining us. We're going to kick off day two of the BFA Vegas Health Care Conference. My name is Mike Riskin. I'm on the Bank of America Life Science Tools and Diagnostics team, and I'm excited to be joined by Sean Vidal, Chief Financial Officer of Medler Toledo. Sean, great to have you. Great. Hey, great to be here, Mike. Thanks for having us. Always a pleasure. Format will be a fireside chat. If anyone in the audience has a burning question, don't hesitate to raise your hand and we'll throw you in. Sean, maybe just to kick things off, you know, you reported 1Q results just a couple days ago. It feels like a lifetime, but I think it's only been three or four days. A lot of moving pieces in the quarter. A lot of debate on how it played out relative to expectations and sort of like what the moving pieces are. Maybe you could just start there and run us through high level, you know, what happened relative to your expectations or how it impacts your view going forward.
Yeah, sure. Hey, so maybe a few comments. Hey, the first thing I don't want to get lost in the quarter is that, you know, we felt really good about our earnings growth in the quarter. You know, we had very strong earnings growth, 9% growth, and I think a more difficult environment. And, you know, I think that really comes back to not only execution, but really says a lot about the culture and the agility of the organization. And as we kind of kind of talk through things today, you know, we want this one of the messages we want to lead people with is that we feel really good about our ability to drive strong earnings growth. When we kind of go to the top line, you know, so we delivered 3% growth that was in line with our guidance, but we acknowledge it included a little bit more M&A contribution. So at the beginning of the quarter, we were expecting M&A to be more about 1%. It was 1.5%. And so with the rounding, the organic growth was 1% versus our 2% organic guide. But, you know, maybe a couple things that I also don't want to get lost in the print is that, you know, we're seeing increasingly good trends in China. I'm sure we'll have an opportunity to talk a little bit more about that. But China was really good, certainly better than our expectations. Our product inspection business, which we talked a little bit on the call, had very strong growth reported, but also organically. The service business continues to do well. We've talked a lot about in the past about how important that is as an opportunity. And within lab, there were pockets of some good things, you know, bioprocessing being one of the examples. But, of course, there was some softness in some of the other businesses, both in lab but also in our core industrial business. You know, when we started the year, we... We did expect things to start a little slow, and that's kind of how we communicated. We just felt like after last year, we felt like companies might be a little bit more hesitant with releasing capital, and clearly that's what we saw. And there was different things that happened in the quarter, starting with some tariff threats at the beginning. Of course, we had a war in the middle. And those things obviously create a little bit of uncertainty for the market and probably had some effect as well. But when you step back from all that, our organization remains positive. We really do. I know we have a little bit more of a cautious outlook for the second quarter, probably reflecting a little bit the dynamic environment. But also when we look at our internal pipeline, we're very encouraged, and I'm sure we'll talk a little bit more about that in a little bit. But then when you kind of look through all this, you know, we feel like we are well positioned for the future. And we purposely talked about. Innovation on our call last week. We really believe that that's the fundamentals, right? And when Patrick became CEO, that was one of the things he wanted to do was accelerate the pace of innovation in the company. It's no coincidence that we're talking more about it. We increased investments over the last few years. I thought we had a lot of nice examples of that. As you know, nothing moves the needle individually at Mettler-Toledo, but these are all good opportunities to also engage customers and to drive sales in the future. Okay.
No, that's great. Thanks, Sean. A lot I'm going to follow up on from there. Maybe a point you made earlier in terms of... You're thinking and how you laid out the outlook when you're going into the year. You said you anticipated companies would be hesitant to release capital. I think that's something we've certainly been aware of and tracking closely. Is there any changes in that as you're going through April and May with the tariff uncertainty, with the Iran war? Are there any moving pockets where companies are sort of getting over that hurdle and being, you know, a little bit more open to stepping up and deploying funds?
Yeah, I mean, hey, so maybe a couple things here. So if you think about, like, last year, there were disruptions in the first half of the year, and it kind of created a little bit of a shift versus normal purchasing patterns last year. I feel like this year, I don't want to say it's the same, but I think there's, you know, you can analogize it to it. Like, there's more disruptions in the first half. That's probably going to shift things a little bit more to the back half. Hey, maybe that's a little bit more than what we would have expected when we started the year. But what encourages us is, you know, when we look at not only talk to the organization, but when we look at the pipeline. And, you know, earlier in the quarter, we were hearing a lot of great antidotes about early pipeline building. As we kind of look at the last couple months, we really see the pipeline really continuing to increase. I'm talking when I say pipeline, the sales funnel. And that's very encouraging for us. And now I know we're a short cycle business. And I know we still have a cautious outlook out for the second quarter. But probably what's most important when you look through that is you, you know, when you look at things like earlier indicators, like hot leads, but even more importantly, like opportunities, like the level of opportunities we have is growing very significantly in the organization. And that's something that's very encouraging. And then you kind of combine that with some of the areas where we see momentum building. Like, you know, we keep on talking about China. We really are seeing that developing in a very positive way. I really feel like China is going to be a nice story for us this year. We went through, we've gone through a little bit of a challenging period here over the last few years, but you really can see a lot of positive signs here. So hopefully that will continue to play out. Biopharma, of course, is another area where we see good momentum as well, too. So there is some optimism. We will lap, you know, in Q3, we'll have like a more difficult comp in our core industrial business. But absent that, you know, as we get into Q4, we'll also have some comp benefits as well, too. That will kind of probably be a little bit of a nuance.
I mean, let's stick with the pipeline there and the opportunities you're talking about. Can you talk about visibility into some of that pipeline and that funnel converting? You know, like you said, you are a short cycle business, but you tend to have, you know, pretty good visibility in customer decisions. Three, six months out, do you feel like broadly your visibility is better now than it might have been three, six months ago or throughout 2025? Are there pockets where you're feeling a little bit more comfortable and sort of, you know, maybe weight the likelihood of some of those converting?
Yeah, I mean, it's always difficult in our business, right? Like we still, as everyone knows, we're still short cycle. Things can change. But what we see is this momentum that's been continuously building. And, you know, the heart of the pipeline or the sales funnel is showing a lot of strength. Our conversion rates are also improving, which also is a sign of, you know, of strength. So that's encouraging, you know, to us. And, you know, in terms of, and then when you kind of combine that with maybe some of the external things, you know, like PMI is getting better, you know, we're, I think we're less cyclical today than we were 10 years ago, but it doesn't hurt, right, especially on the core industrial side. And then as you think about replacement cycles and onshoring and all these things that we didn't, quote, build into the guidance this year, they're still out there as opportunities, especially on the replacement cycle side. And then when you think about, again, where the hot opportunities in the market are, like trends towards automation as companies are reshoring or anything with inflation, everyone's looking for more productivity, and we continue to see good growth in those areas, as well as digitalization. You think about as companies are doing their own AI programs, they're looking to extract information out of their instruments. We're a perfect fit for that. We provide solutions all the way through the value chain, whether you're in the laboratory where we have LabX to really facilitate that. And I think you know on a QA, QC bench, we can sell up to 40% of the instruments on a typical lab bench. But with LabX, we can automate workflows, but also collect data and also ensure data integrity. And then on the industrial side, there's all kinds of things that we're doing with process control, with our terminals, and enable a lot of things on the digital side. And when you can provide things in a structured manner for your customers, it's very effective. And I think it's something that's very valued, especially when you can do it in a very cyber-secure way, too.
One last point on that demand funnel and improving early opportunities. Just from a timing perspective, you mentioned second quarter, more cautious outlook. Is that a second-half opportunity then? You mentioned you do have some comps there, but will we see some of that flow through in the second half? Could that be more of a 1Q, 2Q27 story? For which part? Just the lead times on the improving pipeline.
I mean, hey, I would expect the things that we're seeing in the pipeline will be a second-half story.
Okay. All right. Let's touch on some of the slightly more negative data points from the quarter. And one, obviously, the crisis in the Middle East. You talked about oil as an input cost, so both from a P&L perspective but also from a customer demand perspective, just where are you seeing maybe pockets of caution as a result of that? You know, is it tangible yet? Is it still, you know, more on the delay side of things? Maybe let's talk through that both from a product segment perspective but also from a geographic perspective.
Yeah, sure. So, I mean, so like you said, there's two parts to inflation, right? There's your direct costs on that one. Of course, we're seeing inflationary pressures. I think our organization does a great job of responding to those pressures. And, you know, whether it's through cost savings initiatives or through our pricing program, when we guided, we acknowledge that we have some benefits from tariffs this year at the lower rate, which is a number that is Very similar to what we're seeing on the inflationary side. And then so we, as a result, we took a more cautious view on how we built in some of the mitigation actions. So as we kind of do those over the summer, we'll provide an update. And, you know, perhaps that's a little bit of an upside in the second half. But it's a dynamic environment, as you know, too. And so I think it's better to be cautious at this point. The bigger question, I think, is what you kind of get to is what does it mean to our customers? You know, I feel like with uncertainty, you know, there's two elements. There's the uncertainty part, but then there's also, like, the real cost and is their wallet smaller? You know, segments of the market that have been more affected by that in the past would be, like, the chemical market. And when I say chemical for Mettler Toledo, that means largely specialty chemical, and that's about a low double-digit part of our business. We talked a little bit about that on the call, and I think that, you know, that could be a softer end market for us this year. We'll see how it plays out. But I would also acknowledge that, you know, we've been through higher energy costs. And, you know, Europe is the one that stands out here. You know, they usually kind of get squeezed on these topics when it comes to energy. And we've seen that in the past, like with the war in Ukraine, and we've still done very well. And I think part of it is for us is to like on one hand, you don't stand still, right? You need to look for where are the opportunities in the market and pivot towards where there are opportunities. And there are plenty of opportunities still in Europe, like biopharma is one of them. The other thing that was encouraging to me is that despite that backdrop, I think Europe has actually an improved Q2 outlook. And when we talk about funnel and pipeline, they're right there. You know, and so it's not like we're looking at the European pipeline and panicking it by any means at this point. So I think as we go through the year, there's going to be some segments that are going to be, you know, have a lot more opportunity and hot. And then there's going to be some areas that are maybe a little bit weaker. And then I think, you know, comps will play out, too, depending on the quarter with the segment and things like that.
Okay. And that, especially chemicals, a little over 10%, a little bit of a digit, is part of the business. That's global. That's not just in Europe.
Yes.
Yeah.
Yeah, that's a global number. I don't know the breakdown by region. It might be a little bit larger when we get into China, which is a good example of like, you know, maybe that's a weak segment there, but we're much more optimistic on China.
Yeah, and you're seeing pressure there a little bit everywhere. It's not just here. I mean, let's pivot to China then. You mentioned a couple times in your remarks already, feeling more and more encouraged there. I mean, can you dig a little bit more into that, lab versus industrial? Where are their pockets of strength? Sort of what's driving that?
Yeah, I mean, so, you know, so Europe's had, I think, a few quarters in a row of showing nice growth, kind of improving from... China or... I'm sorry, did you ask about China? It's China, yeah. Yeah, did I say China? You said Europe. Sorry. I'm sorry. Sorry. I was thinking China. I'm sorry. Thanks. So China's had three quarters in a row of increasing growth. Thank you for clarifying. You know, the thing that probably stands out to me the most, we've always said in the past, hey, things in China can change quickly one way or another. I'm really hoping that this one is going in the good direction. You know, we had a bit of a reset, you know, here a few years ago in the economy there, you know, kind of coming out of COVID and everything. But the one thing that stands out is the industrial business. You know, I would say when we started last year, 2025, you know, when I was kind of like. You know, kind of like thinking about what am I really have my eye on? Chinese industrial was one of them, because it was like one of those moments where, you know, what is going to happen in the economy there, it is going to be a little bit more correlated. And, you know, and a lot of these other topics, you know, are at play there. And this business is actually doing very well. And we've had three quarters in a row there. The industrial business grew higher than the 4% that we reported. I think it was like mid to high single digit. And as we think about China improving throughout the back half of the year, I think industrial will be a leader here. And one of the things that's interesting about that is I know there's been a lot of questions over the past year about local competition. And in China, we have the most local competition on industrial. And so I think it shows the strength of our organization, the strength of our China for China strategy, and the things that we're doing locally to innovate and deliver solutions to the customers. This is a great example of Spinnaker. I talked about one segment being soft, but you pivot to the ones that grow. In China, there's a lot of hot segments right now. Our team is doing a great job identifying them, pursuing them, and capturing them. The battery segment is heating up again. It went through really a pullback here a couple of years ago, but that's a good example. Clean Energy is another good example. Semiconductor is another good example. Biopharma in general, especially in the manufacturing side, is showing improvements. I think there's a lot of opportunities there in the future when you start thinking about GLP-1 and generics going forward. So we continue to be optimistic here, and it's nice to see it start to show up in the results.
I mean, you mentioned a couple quarters in a row, seeing some strength there, but as you also said, it can change and it can pivot really quickly. Are you still embedding some caution in the outlook there, just in case it does turn, given some of them?
Yeah, I think, yeah, I mean, you know, in this environment, it's always hard to, like, you know, get it perfect, but I'd like to think there's probably more upside to that one than there is downside from what I see right here, like, when I think about momentum, when I think about funnel and what's going on in that market. But like you said, like, who knows what happens geopolitically going forward, but I, you know, I'm more optimistic.
Okay. Sticking on the topic of China, but you also mentioned biopharma, moving beyond industrial, GOPs, local innovation, local biotech infrastructure. That's been coming up more and more among other tools vendors as well. You're seeing a nice turn there recently. What have you seen for more of the biopharma side of things in China? And then we can probably pivot to biopharma.
On China? You know, so I'd say lab overall has been slower in China relative to our other areas. Like on the industrial side, we're seeing actually better growth on pharma. On the lab side, I'd say it's not bad, but it's not at the levels that we've seen with industrial. Now, when I look at the funnel, the funnel actually looks very good there. And I still think in the short term, industrial will do better. But I think, you know, medium to long term, there's a really great opportunity there. Like you said, like with the GLP-1s and with just the government's focus on developing its own life science industry, I think we have a lot of opportunity there.
And let's pivot to bioprocess in the lab a little bit more globally. You know, you said the lab still remains under pressure for various reasons, but bioprocessing needs to be a bright spot. You know, you've talked about that a little bit more over recent years. Remind us of your exposure to bioprocessing, sort of where are you positioned in the workforce stream and, you know, how well has that been going for you?
Yeah, I mean, very well. I mean, you know, so life sciences in general is about 40% of our business. That includes small and large molecule throughout the value stream. I think bioprocessing as just a category is probably low double digit, and a lot of our exposure here is in process analytics, but we also do a lot of things with some instrumentation and then also with our industrial process control solutions. On the process analytics business, we were the first company to have sensors inside of a bioreactor, so we've always had a leadership position here. It's a very significant, more than half of our process analytics business. We're measuring a lot of different attributes in the reactor, pH being like a strong foot, but a lot of other parameters as well. We are upstream and downstream. Our historical strength was upstream. With the Pendotech acquisition, we kind of strengthened our downstream exposure, and Pendotech also helped us strengthen our single-use exposure as well, too. You know, so we're, you know, we, you know, like everybody else, I think we're very positive on this as an opportunity. We saw particularly good growth, I'd say, in the United States in Q1. You know, we, you know, we were kind of hearing from our team, at least that there was a little bit more prioritization on the U.S. in terms of investments from a lot of our customers. But what's encouraging is that when we look at our Q2 outlook, our European forecast for those businesses looks quite good as well, too. And so I think this will be very much a global theme. I think, you know, from our perspective, we feel very good about it. And I think a lot of the activity that we're seeing in our business is on the consumable side and not quite yet getting all the benefits from facility expansion. So that could be a more positive one as we kind of look to the future.
I mean, on that topic, you know, I assume you're talking about reshoring, onshoring, past the expansion. Yeah, it's been talking about a lot as an out-year benefit. What are you seeing on that? Is there, you know, is there talk about it? Are we in the planning stage? You know, there's a lot of debate on brownfield refurbishment versus new greenfield opportunities. So what are you seeing in terms of what's happening on the ground?
Yeah, I'm hearing more and more stories of engagement with, you know, some of the system integrators and, you know, the engineering firms that do a lot of these projects. So that's been a really good sign. Timing is still a little bit difficult to tell when it's going to happen. Of course, there's been, you know, some activity, you know, like if you think about like semiconductor investments in, you know, like every country in the world, but like the United States as well, you know, we sell a lot of different applications through their value stream, a lot of pure Ultra-pure water applications for cleaning, but also analytical instruments, industrial equipment. There's a lot of ways that we can help that industry, and we certainly have seen, you know, little pockets of that, and it resonates a lot in our process analytics business as well, too.
Okay. Earlier in your remarks, I think you talked about, you know, AI opportunity at pharma, sort of how it's changing the game in terms of... What pharma is able to do, where they're investing, where they're putting money. Are you seeing that being deployed already? Is that a hypothetical discussion? Is that being broadleaved up? Where are we in the pharma leveraging AI? And when you do leverage it, how does Metalware come into play? Where do you benefit there?
Yeah, I mean, you know, I don't know if I'm the best source for that one, but I know it's a topic. I know it's a priority. I do hear about conversations in R&D labs about, you know, how people want to, you know, make investments in this area for obvious reasons. You know, from our perspective, I think Mettler is a great partner for these companies in this regard. You know, when you think about it, like, you know, the first step is really collecting data, right? And when you have a very broad range of instruments, you know, at a company, you know, and we have a great software package. And by the way, we just came out with the latest version of LabX. It really facilitates this, you know, to really collect information in a very structured and in good way. And like, you know, data is everything when it comes to any technology, right? And so really, I think we're a great partner and enabler for this. But it's not only in the lab side, right? It's going to be also on the industrial side. And if you like look at our... We're also doing things to our products to also, you know, leverage AI technologies. Like we'll have like AI wizards and some of our instruments, right, where it can like start to, you know, kind of get to the result a little bit faster. We're using imaging technology in a couple areas in the business. That's like really, you know, whether that's AI or not, it's digitalization, you know, which is a broader theme from my perspective. And we're doing a lot of great things there, too, that are really providing differentiated solutions that are allowing customers to gain new insights and gain productivity. And then we're doing a lot of these things in an automated or semi-automated way, right? And so that's also the big hot topic in labs is we want to do more, but we also want more productivity. And so I think the companies that do a good job of enabling these trends are the ones that are going to be the most successful in the future.
Okay. Yeah. I mean, when you talk about data collection and just sort of more inputs going into the pharma R&D, I think the automation will be sort of the first way to do it. Is that where you're seeing the most interest in pharma? Are you seeing any green shoots there?
I mean, we already have a lot of things that we're doing with partnerships and collaborations that we've talked about in the past in that area. And I continue to think like those are going to be areas that you'll hear more and more about as we kind of go forward. Yeah.
Okay. Okay. We've got a couple minutes left. I want to ask sort of a little bit more of a bigger picture, longer term question. You know, we talked about the various moving pieces as you get through 2026. You've got the comms dynamic, like you said, a little bit softer 2Q guide, but, you know, potentially some opportunities and some better funnel for the second half. As you exit this year and go into next year, sort of how do you see some of those swing factors for growth shaking out? And can you sort of like bridge us from, you know, your exit rate this year into 27, 28 and beyond? Sort of what keeps you optimistic there?
Yeah, I mean, hey, I think, you know, like, I mean, of course, we don't want to provide any guidance or any insights on 2027, you know, at this point in time. I mean, you know, pharma is going to be a big topic for us, you know, it's 40% of our business. I think these trends and automation, as well as companies' digital programs, is going to continue to accelerate. We've been talking about it for a while. We continue to see good growth opportunities in these areas. I think that's going to be a really good one for us. I think China, we've talked a lot about today, but also broader emerging markets. Emerging markets last year outside of China were just slightly bigger than China, and we see a lot of momentum in these countries, India being a good example, Southeast Asia, Korea. And so I think that's a good one for us going forward. I think this topic of replacement cycle, you know, like certainly is something that I think we're all looking forward to seeing kicking in more. And then, of course, the unshoring topic, you know, like, you know, 50% of our business is sold into the production area of a customer. 20% approximately is sold into QAQC. We clearly will be a beneficiary as this trend kicks in. As a global company, we move well with these companies, and especially on the industrial side, when you have a lot of local competition, I think it's going to really be a strength for us kind of going forward. So those are the things on our mind, probably no surprises there. And, you know, hey, we'll see how things play out. And, of course, we'll provide more insights and thoughts as we kind of get to, you know, November of this year.
Okay. Okay. Last couple minutes. Let's talk a little bit about margins and operating leverage, you know, despite some of the pressures on top line. And you're talking about tariffs, input costs. You're still delivering, you know, healthy margins and EPS, both in the first quarter and for the year. You know, what's driving that operating leverage this year? And again, sort of like a healthy jumping off point for next year.
Yeah, I mean, you know, so our operating margin guidance, just for those who are updating models, it's similar to what it was last quarter. Optically, there's a lot of currency, as you know. I think it's like 50 or 60 basis points on the full year in terms of a headwind. But when you subtract that, I think it actually looks quite good. I feel really great about the programs we have right now, whether it's Stern Drive, whether it's our productivity and cost savings programs, but also our pricing program. And the pricing program is great because it really is a great indicator of our value proposition and what customers appreciate. And if you're delivering value, then someone's going to be willing to pay because they're getting a payback on it. And I think that our whole setup has always been great where we're selling often directly to the end user. Our average price point is less than $10,000. When you sell directly, that person can articulate that value proposition. When you're selling to the end user, they understand it. And like I said earlier, we've been investing into that. And I think that whole flywheel has worked really well for us. And, of course, we have a really good program around it with a lot of analytics and stuff where we try to make sure we get the right price point. And we have a lot of our own digital tools that can help us make sure that we're providing the right price point to a customer.
Okay. We're pretty much at the top of the slot, Sean. Any last concluding remarks or anything we missed, anything you want to leave investors with as they walk away?
Yeah, hey, we fully recognize this as a dynamic environment, and it can be a little bit distracting. I hope people can look through that, and as we look to the future, we feel like we're really well positioned. I think Mettler Toledo has a long history of execution. We have really great corporate programs that help drive these opportunities. But probably most important, we have a great culture. You know, I think the culture of Mettler Toledo, I've been around for not quite 30 years. I'm getting there. Hard to believe, but I'm not the only one, right? And I think it says a lot about people are really passionate about our company and there's a really great spirit of collaboration. And I feel like like a lot of companies around the world, we've certainly become a lot more agile in the last five or six years. And I think that's going to ultimately be key for any company going forward is that that agility muscle and just like, hey, things are going to change. It's OK. But how do you respond to it? That's what matters. And I feel that's what I feel best about.
Great. That's a good place to end it. Thanks so much, everyone. Sean, thank you. Thanks, Mike. Appreciate it. Thanks.
0:00 to 30:19 · One card per analyst, follow-ups included. Each plays from its start, and the one being answered is marked.
Thanks for joining us. We're going to kick off day two of the BFA Vegas Health Care Conference. My name is Mike Riskin. I'm on the Bank of America Life Science Tools and Diagnostics team, and I'm excited to be joined by Sean Vidal, Chief Financial Officer of Medler Toledo. Sean, great to have you. Great. Hey, great to…
Shawn Vadala: Yeah, sure. Hey, so maybe a few comments. Hey, the first thing I don't want to get lost in the quarter is that, you know, we felt really good about our earnings growth in the quarter. You know, we had very strong earnings growth, 9% growth, and I think a more…